BioSig Announces Pricing of Public Offering of Common Stock
June 24 2022 - 9:30AM
BioSig Technologies, Inc. (NASDAQ: BSGM) (“BioSig” or the
“Company”) a medical technology company advancing electrophysiology
workflow by delivering greater intracardiac signal fidelity through
its proprietary signal processing platform, today announced pricing
of its previously-announced best efforts underwritten public
offering of up to 4,666,667 shares of its common stock, $0.001 par
value per share, at a price to the public of $0.75 per share. The
gross proceeds to BioSig from this offering are expected to be
$3,500,000.25, before deducting the underwriting discount and other
estimated offering expenses payable by BioSig. The offering is
expected to close on June 28, 2022, subject to customary closing
conditions.
Laidlaw & Company (UK) Ltd. is acting as sole book-running
manager for the offering.
BioSig intends to use the net proceeds from the offering for the
continuation of commercialization activities related to the PURE
EP™ System, including additional support for organizational
development, to fund working capital, and for general corporate
purposes and other capital expenditures.
A shelf registration statement on Form S-3 (Registration No.
333-251859) relating to the public offering of the shares of common
stock described above was previously filed with the Securities and
Exchange Commission (SEC) and declared effective on January 12,
2021. A preliminary prospectus supplement and accompanying
prospectus relating to the offering have been filed with the SEC
and are available on the SEC’s website at www.sec.gov. A final
prospectus supplement and accompanying prospectus relating to the
underwritten public offering will be filed with the SEC and will be
available on the SEC’s website at www.sec.gov. Copies of the final
prospectus supplement, when available, and accompanying prospectus
relating to the offering may be obtained from Laidlaw & Company
(UK) Ltd., 521 Fifth Ave., 12th Floor, New York, NY 10175,
Attention: Syndicate Dept.; email: syndicate@laidlawltd.com.
This press release shall not constitute an offer to sell or the
solicitation of an offer to buy these securities, nor shall there
be any sale of these securities in any state or other jurisdiction
in which such offer, solicitation or sale would be unlawful prior
to registration or qualification under the securities laws of any
such state or other jurisdiction. Any offer, if at all, will be
made only by means of the prospectus supplement and accompanying
prospectus forming a part of the effective registration
statement.
About BioSig Technologies
BioSig Technologies is a medical technology company
commercializing a proprietary biomedical signal processing platform
designed to improve signal fidelity and uncover the full range of
ECG and intra-cardiac signals (www.biosig.com).
The Company's first product, PURE EP(TM) System, is a novel
signal processing and acquisition platform designed to extract
advanced diagnostic and therapeutic data that enhances physician
workflow and increases throughput. PURE EP(TM) was engineered to
address the limitations of existing EP technologies by empowering
physicians with superior signals and actionable insights.
Forward-looking Statements
This press release contains “forward-looking statements.” Such
statements may be preceded by the words “intends,” “may,” “will,”
“plans,” “expects,” “anticipates,” “projects,” “predicts,”
“estimates,” “aims,” “believes,” “hopes,” “potential” or similar
words. Forward- looking statements are not guarantees of future
performance, are based on certain assumptions and are subject to
various known and unknown risks and uncertainties, many of which
are beyond the Company’s control, and cannot be predicted or
quantified and consequently, actual results may differ materially
from those expressed or implied by such forward-looking statements.
Such risks and uncertainties include, without limitation, risks and
uncertainties associated with (i) market conditions, the
satisfaction of customary closing conditions relating to the public
offering and the Company’s intended use of proceeds, (ii) the
geographic, social and economic impact of COVID-19 on our ability
to conduct our business and raise capital in the future when
needed, (iii) our inability to manufacture our products and product
candidates on a commercial scale on our own, or in collaboration
with third parties; (iv) difficulties in obtaining financing on
commercially reasonable terms; (v) changes in the size and nature
of our competition; (vi) loss of one or more key executives or
scientists; and (vii) difficulties in securing regulatory approval
to market our products and product candidates. More detailed
information about the Company and the risk factors that may affect
the realization of forward-looking statements is set forth in the
Company’s filings with the Securities and Exchange Commission
(SEC), including the Company’s Annual Report on Form 10-K and its
Quarterly Reports on Form 10-Q. Investors and security holders are
urged to read these documents free of charge on the SEC’s website
at http://www.sec.gov. The Company assumes no obligation to
publicly update or revise its forward-looking statements as a
result of new information, future events or otherwise.
Andrew Ballou
BioSig Technologies, Inc.
Vice President, Investor Relations
55 Greens Farms Road
Westport, CT 06880
aballou@biosigtech.com
203-409-5444, x133
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Aug 2024 to Sep 2024
BioSig Technologies (QB) (USOTC:BSGM)
Historical Stock Chart
From Sep 2023 to Sep 2024